MIRATI THERAPEUTICS INC (MRTX) Stock Price, Forecast & Analysis
USA - NASDAQ:MRTX - US60468T1051 - Common Stock
MRTX Key Statistics, Chart & Performance
The current stock price of MRTX is 58.7 USD. In the past month the price decreased by -0.44%. In the past year, price increased by 10.57%.
MRTX Latest News, Press Relases and Analysis
MRTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About MRTX
Company Profile
Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. The company is headquartered in San Diego, California and currently employs 587 full-time employees. The company went IPO on 2013-07-12. The firm is developing novel therapeutics to address the genetic and immunological promoters of cancer. The firm's product KRAZATI is an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Its MRTX1133 is an investigational, selective, and potent KRAS G12D inhibitor. Its MRTX1719 is an investigational synthetic lethal PRMT5 inhibitor designed to specifically target the PRMT5/ methylthioadensoine (MTA) complex. Its MRTX0902 is a potent, selective SOS1 inhibitor, designed to improve anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors. Its Sitravatinib is an investigational spectrum-selective kinase inhibitor designed to potently inhibit receptor tyrosine kinases (RTKs) and enhance immune responses through the inhibition of immunosuppressive signaling.
Company Info
MIRATI THERAPEUTICS INC
3545 Cray Court
San Diego CALIFORNIA 92121 US
CEO: Charles M. Baum
Employees: 587
Phone: 18583323410
MIRATI THERAPEUTICS INC / MRTX FAQ
What does MRTX do?
Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. The company is headquartered in San Diego, California and currently employs 587 full-time employees. The company went IPO on 2013-07-12. The firm is developing novel therapeutics to address the genetic and immunological promoters of cancer. The firm's product KRAZATI is an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Its MRTX1133 is an investigational, selective, and potent KRAS G12D inhibitor. Its MRTX1719 is an investigational synthetic lethal PRMT5 inhibitor designed to specifically target the PRMT5/ methylthioadensoine (MTA) complex. Its MRTX0902 is a potent, selective SOS1 inhibitor, designed to improve anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors. Its Sitravatinib is an investigational spectrum-selective kinase inhibitor designed to potently inhibit receptor tyrosine kinases (RTKs) and enhance immune responses through the inhibition of immunosuppressive signaling.
What is the stock price of MIRATI THERAPEUTICS INC today?
The current stock price of MRTX is 58.7 USD. The price decreased by -0.17% in the last trading session.
Does MRTX stock pay dividends?
MRTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of MRTX stock?
MRTX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
On which exchange is MRTX stock listed?
MRTX stock is listed on the Nasdaq exchange.
Can you provide the growth outlook for MIRATI THERAPEUTICS INC?
The Revenue of MIRATI THERAPEUTICS INC (MRTX) is expected to grow by 406.04% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
MRTX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to MRTX. When comparing the yearly performance of all stocks, MRTX turns out to be only a medium performer in the overall market: it outperformed 69.11% of all stocks.
MRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to MRTX. MRTX has a great financial health rating, but its profitability evaluates not so good.
MRTX Financial Highlights
Over the last trailing twelve months MRTX reported a non-GAAP Earnings per Share(EPS) of -12.22. The EPS increased by 8.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -64.25% | ||
| ROE | -76.69% | ||
| Debt/Equity | 0 |
MRTX Forecast & Estimates
22 analysts have analysed MRTX and the average price target is 62.42 USD. This implies a price increase of 6.34% is expected in the next year compared to the current price of 58.7.
For the next year, analysts expect an EPS growth of 14.07% and a revenue growth 406.04% for MRTX